Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
04/24/2022 - 01:00 PM
- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT)
SOUTH SAN FRANCISCO, Calif., April 24, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 FILLMORE monotherapy trial for AMT-101 (GI- selective, oral fusion of IL-10) in patients with chronic pouchitis in a premarket press release and webcasted conference call on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT).
Conference Call & Webcast Information To participate in the conference call, please dial (844) 422-9742 (Domestic) or (706) 758-6032 (International) and refer to conference ID 5649019. The live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events .
About Applied Molecular Transport Inc. AMT is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT is developing additional oral biologic product candidates in patient-friendly oral dosage forms that are designed to either target local intestinal tissue or enter systemic circulation to precisely address the relevant pathophysiology of disease.
AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com .
Investor Relations Contact: Andrew Chang Head, Investor Relations & Corporate Communicationsachang@appliedmt.com
Media Contacts: Alexandra Santos Wheelhouse Life Science Advisorsasantos@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transport Inc
AMTI Rankings
N/A Ranked by Stock Gains
AMTI Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About AMTI
applied molecular transport is developing a pipeline of transformative, targeted oral biological therapeutics that promise to redefine the future of biopharmaceuticals. our deep scientific foundations in mucosal immunology and microbiome-epithelial interfaces have led to the development of powerful technology platforms that are fueling a unique pipeline of first-in-class molecules to treat a wide range of grievous diseases. our oral biopharmaceutical products mimic the biology of microbial and other natural processes that modulate health and disease via mucosal immunology pathways. our targeted therapeutics are directed to the right location to intercept disease at the point of origin of dysregulation. we are advancing a pipeline of targeted oral biological therapeutics to treat autoimmune, inflammation and other diseases, including those associated with cancer, metabolic and hepatologic disorders. our overriding patient-centric goal is to open new biological possibilities based on nov